NEW YORK, NY / ACCESSWIRE / November 26, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Turquoise Hill Resources Ltd. (NYSE: TRQ)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/turquoise-hill-resources-ltd-loss-submission-form?prid=11234&wire=1
Lead Plaintiff Deadline: December 14, 2020
Class Period: July 17, 2018 - July 31, 2019
Allegations against TRQ include that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost and timing of production; (iii) the company's publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.
Zosano Pharma Corporation (NASDAQ: ZSAN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11234&wire=1
Lead Plaintiff Deadline: December 28, 2020
Class Period: February 13, 2017 - September 30, 2020
Allegations against ZSAN include that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Interface, Inc. (NASDAQ: TILE)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/interface-inc-loss-submission-form?prid=11234&wire=1
Lead Plaintiff Deadline: January 11, 2021
Class Period: March 2, 2018 - September 28, 2020
Allegations against TILE include that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share ("EPS") in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC's investigation, and downplayed the true scope of the Company's wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong